<div>
                                <figure class="article-image__container">
                                    
                                    
                                    
                                    <img src="https://imageproxy.pbkrs.com/https://www.pharmaceutical-technology.com/wp-content/uploads/sites/24/2025/12/shutterstock_2514407931-430x241.jpg?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" width="430" height="241" original-src="https://imageproxy.pbkrs.com/https://www.pharmaceutical-technology.com/wp-content/uploads/sites/24/2025/12/shutterstock_2514407931-430x241.jpg"/>
                                    
                                    <figcaption>Brelovitug neutralises hepatitis D and hepatitis B viruses by binding to surface antigens. Credit: Vink Fan via Shutterstock.com.</figcaption>
                                </figure>
                            </div>
                                             
     
<p>Mirum Pharmaceuticals has agreed to acquire Bluejay Therapeutics in a deal worth up to $820m, adding a Phase III liver disease candidate to its portfolio.</p>



<p>According to the agreement, US-based Mirum will pay $250m in cash and $370m in its own stock upfront to buy the private biotech. Bluejay is also in line to receive a further $200m in potential sales-based milestones.</p><div>
<div id="div-gpt-ad-6065588-4"></div>
  
</div><div><div>
                   <div><h3>Go deeper with GlobalData</h3><ul><li><div><figure><img src="/wp-content/themes/goodlife-wp-B2B/assets/img/report.png" alt="ReportsLogo" original-src="/wp-content/themes/goodlife-wp-B2B/assets/img/report.png"/></figure></div><div><div>Reports 
                                                                
                                                                    
                                                                    
                                                                
                                                            </div><h4>LOA and PTSR Model - Bexmarilimab in Acute Myelocytic Leukemia (AML... </h4></div> </li><li><div><figure><img src="/wp-content/themes/goodlife-wp-B2B/assets/img/report.png" alt="ReportsLogo" original-src="/wp-content/themes/goodlife-wp-B2B/assets/img/report.png"/></figure></div><div><div>Reports 
                                                                
                                                                    
                                                                    
                                                                
                                                            </div><h4>LOA and PTSR Model - Bexmarilimab in Myelodysplastic Syndrome </h4></div> </li></ul> <div>
                    <h5>
                                                Go deeper with GlobalData
                                            </h5>
                    <p>
                        The gold standard of business intelligence.
                    </p>
                    <p>
                            Find out more
                            
                                
                            
                        
                    </p>
                </div>
                </div></div><section><figure><img src="https://imageproxy.pbkrs.com/https://www.pharmaceutical-technology.com/wp-content/themes/goodlife-wp-B2B/assets/images/GMS-logo.svg?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://www.pharmaceutical-technology.com/wp-content/themes/goodlife-wp-B2B/assets/images/GMS-logo.svg"/></figure><h4> Discover B2B Marketing That Performs </h4><p>
						Combine business intelligence and editorial excellence to reach engaged professionals across 36 leading media platforms.
					</p><p>
							Find out more </p></section></div>



<p>The deal gives Mirum access to brelovitug, Bluejay’s monoclonal antibody (mAb) currently being evaluated in a Phase III trial for chronic hepatitis D, a rare and severe liver infection for which there are no US Food and Drug Administration (FDA)-approved therapies. Gilead’s Hepcludex (bulevirtide) is approved as a hepatitis D treatment in the EU.</p><div id="slot-one"></div><div id="Sgpollsputhere"></div>



<p>Only occuring in people already infected with hepatitis B due to the surface proteins needed for viral replication, chronic hepatitis D is considered the most severe type of chronic viral hepatitis and leads to cirrhosis, liver failure, and liver cancer.</p>



<p>Brelovitug neutralises hepatitis D and hepatitis B virusus by binding to surface antigens, clearing hepatitis B Surface Antigen (HBsAg)-containing particles and activating antigen-specific T cells.</p>



<p>In November 2025, Bluejay reported positive data from a Phase II study evaluating brelovitug in patients with chronic hepatitis D. The drug achieved a 100% virologic response, along with beneficial effects on liver inflammation and viral load reduction.</p><div> 
                         <div>


            <div>

                <img src="/wp-content/themes/goodlife-wp-B2B/assets/images/strategic-int.png" alt="" original-src="/wp-content/themes/goodlife-wp-B2B/assets/images/strategic-int.png"/>
            </div>


            <div>

                <span class="gdm-company-profile-unit__form-excerpt">GlobalData Strategic Intelligence</span>
 <div id="gdm-form-wrapper">



                    <h1>
                        US Tariffs are shifting - will you react or anticipate?
                    </h1>
                    <p>Don’t let policy changes catch you off guard. Stay proactive with real-time data and expert analysis.</p>
                    <span class="gdm-company-profile-unit__text">By GlobalData</span>
                
          </div>
          </div>  
           </div> Learn more about Strategic Intelligence</div>



<p>The ongoing global AZURE Phase III programme is currently enrolling patients, with top-line data expected in H2 2026. Mirum anticipates submitting an application to the FDA in 2027, with a launch occurring in the same year.</p>



<p>Mirum said it has also secured $200m through a private placement with new and existing healthcare investors to help fund the drug’s development and commercialisation.</p><div id="slot-two"></div>



<p>Mirum’s commercial portfolio includes Livmarli (maralixibat) for chronic itching due to Alagille syndrome, Cholbam (cholic acid) for bile acid synthesis disorders, and Ctexli (chenodiol) for lipid storage disease cerebrotendinous xanthomatosis.</p>



<p>The latter two products were acquired by Mirum in a buyout of Travere’s bile acid product portfolio for up to $445m in 2023.</p>



<p>Mirum’s CEO Chris Peetz said: “This acquisition fits squarely with what we do best – advancing high-impact medicines for patients with rare diseases through disciplined development, regulatory innovation, and commercial excellence.”</p>



<p>Mirum’s pipeline includes ileal bile acid transporter inhibitor volixibat, which is in two Phase IIb studies (NCT05050136, NCT04663308) for two types of cholangitis. The company also has MRM-3379, a PDE4D inhibitor in a Phase II trial (NCT07209462) for the treatment of fragile X syndrome.</p>



<p>Peetz added: “Brelovitug in hepatitis D leverages our deep expertise in rare liver disease and builds on the relationships we’ve established with key providers through the volixibat and Livmarli programmes.”</p>
<div id="slot-three"></div><p></p>



<div>
    
</div>



                   
               <div>
                 <h2>Pharmaceutical Technology Excellence Awards - Nominations Closed</h2>
                 <p>Nominations are now closed for the Pharmaceutical Technology Excellence Awards. A big thanks to all the organisations that entered – your response has been outstanding, showcasing exceptional innovation, leadership, and impact.
<br/>
<br/>
<strong>Excellence in Action</strong>
<br/>Imagene’s Oncology Intelligence (OI) Suite  has won the Innovation Award for Precision Oncology, for transforming how pharma designs and runs oncology trials. From AI-driven biomarker discovery to smarter patient stratification, see how Imagene is cutting time, cost and risk in cancer drug development.</p>
Discover the Impact

             </div>

MIRM

<p>Mirum Pharmaceuticals will acquire Bluejay Therapeutics for up to $820m, gaining access to Bluejay's Phase III monoclonal antibody brelovitug for chronic hepatitis D. The deal includes $250m cash, $370m in stock, and $200m in sales milestones. Mirum plans FDA submission in 2027, leveraging its expertise in rare liver diseases. The acquisition aligns with Mirum's strategy to advance medicines for rare diseases.</p>

Mirum to buy Bluejay for up to $820m in rare liver disease push